NCT02863913 2019-03-06
PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer
Peking University
Phase 1 Withdrawn
Clinical Trials
4 trialsNCT02867332 2019-03-06
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Peking University
Phase 1 Withdrawn
NCT00224354 2012-05-21
CLONTAK
Baylor College of Medicine
Phase 1 Withdrawn
NCT00937300 2011-11-23
T-cell Based Immunotherapy for Head and Neck Cancer
Herlev Hospital
Phase 1 Withdrawn